13F Portfolios

Commodore Capital LP: RELAY THERAPEUTICS INC (RLAY): Quarterly 13F Position History

As of Q1 2026, Commodore Capital LP reported 17,000,000 shares of RELAY THERAPEUTICS INC (RLAY), worth $169.2M and representing 9.8% of its 13F equity book. The position first appeared in Q2 2025 and has been disclosed across 4 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 4 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 17,000,000 0 $169.2M 9.8% $9.9
Q4 2025 17,000,000 0 $143.8M 9.6% $8.5
Q3 2025 17,000,000 +3,650,000 +27.3% $88.7M 4.3% $5.2
Q2 2025 13,350,000 $46.2M 3.3% $3.5

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Commodore Capital LP first disclose a RLAY position in 13F-HR filings?

Commodore Capital LP first reported RELAY THERAPEUTICS INC (RLAY) on its 13F-HR filing for the period ending 2025-06-30 (Q2 2025). The position has appeared on 4 reported quarters within Pactolio's tracked window.

What was Commodore Capital LP's most recent quarter-over-quarter share-count change in RLAY?

Commodore Capital LP held the same 17,000,000 shares of RLAY between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Commodore Capital LP's cost basis in RLAY?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.